BA 401_Genenteach
•Download as PPT, PDF•
0 likes•360 views
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient production capacity through 2015.
Report
Share
Report
Share
![[object Object],[object Object],[object Object],[object Object],[object Object],Introduction to case Outline](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
BA401_Genentech
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
Orgenesis Investor Corporate Presentation
A science-based organization dedicated to curing disease through the development and manufacture of cell-based therapeutics and regenerative medicine.
BatchMaster ERP for Vaccines
Vaccine development is just the first step in eradicating the pandemic, the real challenge lies in managing and handling its supply chain. An ERP built specifically for Vaccines can be the way out in efficiently fighting these challenges. Go through the presentation to know how exactly an ERP for vaccines helps.
Bioanalytical Capabilities -- Thought-Leading Science Armed with the Latest T...
Helping your drug development program succeed is what we do. Keeping your timeline on track requires scientific expertise, operational experience and up-to-date knowledge of the regulatory environment. Whether you need preclinical or clinical bioanalysis, local support or global capabilities, Covance is the partner that you can trust to help deliver on your bioanalytical timelines every day, every time.
Intelgenx presentation july 2017
IntelGenx is a drug delivery company that develops improved versions of approved drugs using its proprietary drug delivery platforms, VersaFilm and AdVersa. Some of its pipeline products include Rizaport for migraines, Tadalafil VersaFilm for erectile dysfunction, Loxapine VersaFilm for schizophrenia, and Montelukast VersaFilm for mild cognitive impairment. The company has completed clinical trials demonstrating its products offer benefits over existing drugs such as increased bioavailability and reduced side effects. IntelGenx licenses its products to partners and retains manufacturing rights to generate revenue through milestone payments and royalties.
Fertigo Presentation
The document discusses a company called Fertigo Medical that has developed a device to increase IVF success rates by continuously monitoring the uterus to determine the optimal time for embryo implantation. Currently, IVF success rates are only 11-29% per treatment cycle. Fertigo's device uses a mini-probe placed in the uterus to collect morphological parameters and transmit the data, allowing physicians to personalize embryo transfers based on evidence of uterine readiness. The company has completed preclinical and early clinical trials and is seeking funding to continue clinical work and product development to help increase IVF success rates substantially.
Advanced Medical Isotope Corp. Presentation
Vivos Inc. presented a new brachytherapy tool called RadioGel for treating cancers in humans and animals. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle. It is designed to deliver a high radiation dose directly to tumors while minimizing damage to healthy tissue. The company expects to generate near-term revenue from veterinary applications and international licensing as it pursues FDA approval for multiple human cancer indications starting with skin cancer. Vivos has strong leadership and advisors in place and an intellectual property protected platform technology to become an important new tool for cancer treatment.
Business Transformation and Partnering Strategies to Accelerate Commercialisa...
Magda Papadaki PhD, former Head of Manufacturing & Innovation, Association of the British Pharmaceutical Industry (ABPI) and current Associate Director, MSD shares her recent presentation at London's Cell & Gene Therapy Congress 2018, “Business Transformation and Partnering Strategies to Accelerate Commercialisation of Cell & Gene Therapies.”
The presentation includes key information and insights into:
- New Pathways to CGT commercialisation and clinical use
- System Readiness: New Pathways & Collaborations
- Innovating how we Innovate to Deliver Cures.
More information about the 2019 Cell & Gene Therapy Congress can be found here: www.celltherapy-congress.com
Recommended
BA401_Genentech
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
Orgenesis Investor Corporate Presentation
A science-based organization dedicated to curing disease through the development and manufacture of cell-based therapeutics and regenerative medicine.
BatchMaster ERP for Vaccines
Vaccine development is just the first step in eradicating the pandemic, the real challenge lies in managing and handling its supply chain. An ERP built specifically for Vaccines can be the way out in efficiently fighting these challenges. Go through the presentation to know how exactly an ERP for vaccines helps.
Bioanalytical Capabilities -- Thought-Leading Science Armed with the Latest T...
Helping your drug development program succeed is what we do. Keeping your timeline on track requires scientific expertise, operational experience and up-to-date knowledge of the regulatory environment. Whether you need preclinical or clinical bioanalysis, local support or global capabilities, Covance is the partner that you can trust to help deliver on your bioanalytical timelines every day, every time.
Intelgenx presentation july 2017
IntelGenx is a drug delivery company that develops improved versions of approved drugs using its proprietary drug delivery platforms, VersaFilm and AdVersa. Some of its pipeline products include Rizaport for migraines, Tadalafil VersaFilm for erectile dysfunction, Loxapine VersaFilm for schizophrenia, and Montelukast VersaFilm for mild cognitive impairment. The company has completed clinical trials demonstrating its products offer benefits over existing drugs such as increased bioavailability and reduced side effects. IntelGenx licenses its products to partners and retains manufacturing rights to generate revenue through milestone payments and royalties.
Fertigo Presentation
The document discusses a company called Fertigo Medical that has developed a device to increase IVF success rates by continuously monitoring the uterus to determine the optimal time for embryo implantation. Currently, IVF success rates are only 11-29% per treatment cycle. Fertigo's device uses a mini-probe placed in the uterus to collect morphological parameters and transmit the data, allowing physicians to personalize embryo transfers based on evidence of uterine readiness. The company has completed preclinical and early clinical trials and is seeking funding to continue clinical work and product development to help increase IVF success rates substantially.
Advanced Medical Isotope Corp. Presentation
Vivos Inc. presented a new brachytherapy tool called RadioGel for treating cancers in humans and animals. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle. It is designed to deliver a high radiation dose directly to tumors while minimizing damage to healthy tissue. The company expects to generate near-term revenue from veterinary applications and international licensing as it pursues FDA approval for multiple human cancer indications starting with skin cancer. Vivos has strong leadership and advisors in place and an intellectual property protected platform technology to become an important new tool for cancer treatment.
Business Transformation and Partnering Strategies to Accelerate Commercialisa...
Magda Papadaki PhD, former Head of Manufacturing & Innovation, Association of the British Pharmaceutical Industry (ABPI) and current Associate Director, MSD shares her recent presentation at London's Cell & Gene Therapy Congress 2018, “Business Transformation and Partnering Strategies to Accelerate Commercialisation of Cell & Gene Therapies.”
The presentation includes key information and insights into:
- New Pathways to CGT commercialisation and clinical use
- System Readiness: New Pathways & Collaborations
- Innovating how we Innovate to Deliver Cures.
More information about the 2019 Cell & Gene Therapy Congress can be found here: www.celltherapy-congress.com
Globavir Presentation
Globavir is presenting its corporate strategy to target tropical diseases through accelerated drug development. The presentation highlights GBV006, a late-stage drug candidate for the treatment of dengue fever derived from two FDA-approved drugs. GBV006 has shown potent antiviral activity and 100% survival in animal studies. Globavir also has a pipeline of diagnostic tests and is pursuing partnerships to develop and commercialize its products globally.
Ablynx Financial Presentation Half Year Results 2014
1) Ablynx reported strong financial and clinical progress in the first half of 2014, with revenues increasing 72% and a 40% reduction in net loss compared to the same period in 2013.
2) Clinically, caplacizumab achieved proof-of-concept for the treatment of acquired thrombotic thrombocytopenic purpura, and preparations were underway to start a Phase III trial in 2015. Phase I trials were also initiated for other programs.
3) Partnership wise, Merck Serono and AbbVie advanced programs in clinical trials, and a new collaboration was announced with Merck & Co. worth up to €1.7 billion in potential milestones.
Past Present Future Abbott
Abbott Laboratories was founded in 1888 by Dr. Wallace Abbott as a single medical practice and drugstore in Illinois, with total sales of $2,000. Today, Abbott is a global healthcare company with over 68,000 employees in over 100 facilities across 130 countries. Abbott Animal Health has been a division of Abbott for over 25 years, providing leading veterinary products and support to veterinarians worldwide. Looking to the future, Abbott Animal Health continues to develop innovative solutions for animal health through research and partnerships.
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
For additional information, please visit http://www.sqidiagnostics.com
Finding a New Normal While Navigating Through Information Overload
Information and URGENT STEPS every Dental Practice needs to be following to SURVIVE AND HELP THEIR PATIENTS and Team during AND AFTER the Coronavirus Pandemic.
AMI August Investor Presentation
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Abbott Laboratories
Abbott Laboratories SWOT Analysis
Strength 1. Abbott is collaborating with Syngene, India's leading contract research organization, to establish its first nutrition research and development (R&D) center in the country
2. Abbott Molecular has acquired an exclusive license to develop a diagnostic test in the United States based on several new biomarkers
3. Includes a broad range of specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; a spectrum of nutritional supplements for infants, children and adults; and products for veterinary care.
4. Abbott Launches PediaSure SideKicks , a nutritional beverage to help balance out a picky eater's uneven diet
5.Strong employee force of 90,000
Weakness 1. Products listed on the site may be available only in certain countries.
2.Company is overly dependent upon mature products whose patents may expire in near future
3. Abbot faces lot of litigation cases in various countries regarding its products
4. Upcoming patent expires
Opportunity 1. Broad-based medical innovation, in technologies and businesses across the spectrum of health care
2. Pioneering solutions that advance health care
3. Address health needs in under-developed and poor countries
4. Leverage its core business expertise and resources to create sustainable solutions in countries around the world.
Threats 1. Increasing obsolesce of technology
2. Competition from peers
3.Unprecedented generic erosion exacerbated by ineffective product lifecycle launches
4.Government regulation
5.Industry consolidation
Advanced Medical Isotope Corp. Presentation
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Nanobodies: Journey from Research to Commercial
Hilde Revets, Senior Research Fellow, Ablynx
Presentation at EIPG – VAPI-UPIP Symposium “Biotech and Advanced Therapies: Challenges and Opportunities” at the Faculty of Medicine and Pharmacy, Campus Jette, Vrije Universiteit van Brussel, Brussels 2013.
Biogen presentation1
The document outlines the 2007 business goals of Biogen Idec, including goals set by the CEO, CFO and management, and VP of R&D. The CEO's goal of having 100,000 patients on TYSABRI was not met. The CFO and management's goal of over 40% of revenue coming from international business was not met. The VP of R&D's goals of four new products launched or in new indications and six late-stage clinical programs were not met. The regulatory goal of six late-stage programs was achieved.
PBIO Investor Presentation
Pressure BioSciences is presenting their pressure cycling technology instruments and consumables. Their flagship product is the Barocycler 2320EXTREME instrument, which uses high pressure cycling to prepare biological samples for analysis. They have over 270 PCT systems installed worldwide and publications highlighting the advantages of PCT in biopharma sample preparation from discovery to clinical use. The company is poised for growth with their exclusive marketing agreement with SCIEX, expanded sales team, and focus on the multi-billion dollar biopharma market.
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
This document summarizes a presentation on FDA 483 trending topics and solutions. It discusses FDA definitions and common observations related to data integrity, documentation practices, visual inspection execution and documentation of defects, and container/closure integrity. For each topic, it provides examples of recent FDA inspection citations in biologics, devices, and drugs. It also discusses factors that may influence FDA inspections such as regulatory maturity, communication, investigator expertise, and company culture.
Cell Therapy Manufacturing: Regulations and Facilities
This document discusses the regulatory and manufacturing challenges of cell therapy products. It notes that cell therapies must be aseptically processed but cannot be fully sterilized like traditional drugs. The challenges include controlling differentiation of stem cells into the desired target cell type, developing potency assays, and dealing with variability in biological materials. Manufacturing challenges include developing aseptic processing methods, handling adventitious agents, and scaling up production capacity for either autologous or allogeneic use. Larger centralized facilities face quality oversight and logistical issues, while smaller regional facilities could better concentrate expertise, quality, and handling of incoming/outgoing cells and products.
Bharat biotech company Overview
Bharat Biotech’s research stems from the need to innovate and the necessity to address public health requirements of the developing nations, while adhering to IPR. Our business model is to support the advancement of technologies through strong collaborative research, and simultaneously support the establishment of strong innovative technology platforms for intellectual property reputed driven enterprise R&D.
APT_Indigo FactSheet FINAL
The document describes Aptuit INDiGO's accelerated drug development program. It offers integrated services to help clients advance molecules from candidate selection to clinical trials in as few as 52 weeks. This is significantly faster than the industry average of 122 weeks. Aptuit's program provides world-class expertise across preclinical and clinical development, API manufacturing, and regulatory submission preparation to streamline the process. It aims to reduce costs and development time while improving data quality for clients.
New Venture Launch: Funding for trials for important new discovery
New Venture Launch: Funding for trials for important new discoveryWild Out West / Magnity Interactive
The company founder effectively life-hacked a $billion dollar OTC product and was awarded 6 patents for it. The funds raised were to prove efficacy and will probably be the only funding required before licensing.
We took a highly technical breifing and created a story that is both understandable and informative. We developed the brands, strategy, copy, graphics, and put together the deck and arranged key meetings with investors.
www.wildoutwest.comLaunch of a new Pharmaceutical Product
General Investor and partnership presentation for the launch of a new pharmaceutical product. Specifically funds the initial clinical trial and market tests.
Cgix
This investor presentation by Cancer Genetics, Inc provides an overview of the company and its proprietary genomic testing programs. CGI has locations in the US, India, and China serving biopharma, clinical, and research clients. It has launched 7 proprietary diagnostic products focused on hematologic and urogenital cancers, and is working to validate additional next generation sequencing panels. CGI's tests provide information to aid in diagnosis, prognosis, and therapeutic decision making for cancers like CLL, cervical cancer, and kidney cancer. The company is collaborating with academic centers to further develop and validate its genomic tests.
IGXT Jan 20 2017 Investor Presentation
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
Intelgenx Q4 Earnings Presentation
The document summarizes IntelGenx's Q4 and full year 2015 financial results. Key points include:
- Record revenue in Q4 2015 and full year 2015, demonstrating strong execution of their strategy.
- Continued growth of Forfivo XL sales, with Q4 2015 net sales increasing 24% over Q3 2015.
- Completion of construction of a new manufacturing facility that will lower costs and improve quality control.
- Strengthened management team to accelerate business development and product pipeline expansion.
- Outlook for continued revenue growth from commercialization efforts and new product opportunities utilizing their oral thin film technology platform.
wyeth Download Documentation Credit Suisse Group Healthcare Conference
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conference
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
More Related Content
What's hot
Globavir Presentation
Globavir is presenting its corporate strategy to target tropical diseases through accelerated drug development. The presentation highlights GBV006, a late-stage drug candidate for the treatment of dengue fever derived from two FDA-approved drugs. GBV006 has shown potent antiviral activity and 100% survival in animal studies. Globavir also has a pipeline of diagnostic tests and is pursuing partnerships to develop and commercialize its products globally.
Ablynx Financial Presentation Half Year Results 2014
1) Ablynx reported strong financial and clinical progress in the first half of 2014, with revenues increasing 72% and a 40% reduction in net loss compared to the same period in 2013.
2) Clinically, caplacizumab achieved proof-of-concept for the treatment of acquired thrombotic thrombocytopenic purpura, and preparations were underway to start a Phase III trial in 2015. Phase I trials were also initiated for other programs.
3) Partnership wise, Merck Serono and AbbVie advanced programs in clinical trials, and a new collaboration was announced with Merck & Co. worth up to €1.7 billion in potential milestones.
Past Present Future Abbott
Abbott Laboratories was founded in 1888 by Dr. Wallace Abbott as a single medical practice and drugstore in Illinois, with total sales of $2,000. Today, Abbott is a global healthcare company with over 68,000 employees in over 100 facilities across 130 countries. Abbott Animal Health has been a division of Abbott for over 25 years, providing leading veterinary products and support to veterinarians worldwide. Looking to the future, Abbott Animal Health continues to develop innovative solutions for animal health through research and partnerships.
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
For additional information, please visit http://www.sqidiagnostics.com
Finding a New Normal While Navigating Through Information Overload
Information and URGENT STEPS every Dental Practice needs to be following to SURVIVE AND HELP THEIR PATIENTS and Team during AND AFTER the Coronavirus Pandemic.
AMI August Investor Presentation
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Abbott Laboratories
Abbott Laboratories SWOT Analysis
Strength 1. Abbott is collaborating with Syngene, India's leading contract research organization, to establish its first nutrition research and development (R&D) center in the country
2. Abbott Molecular has acquired an exclusive license to develop a diagnostic test in the United States based on several new biomarkers
3. Includes a broad range of specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; a spectrum of nutritional supplements for infants, children and adults; and products for veterinary care.
4. Abbott Launches PediaSure SideKicks , a nutritional beverage to help balance out a picky eater's uneven diet
5.Strong employee force of 90,000
Weakness 1. Products listed on the site may be available only in certain countries.
2.Company is overly dependent upon mature products whose patents may expire in near future
3. Abbot faces lot of litigation cases in various countries regarding its products
4. Upcoming patent expires
Opportunity 1. Broad-based medical innovation, in technologies and businesses across the spectrum of health care
2. Pioneering solutions that advance health care
3. Address health needs in under-developed and poor countries
4. Leverage its core business expertise and resources to create sustainable solutions in countries around the world.
Threats 1. Increasing obsolesce of technology
2. Competition from peers
3.Unprecedented generic erosion exacerbated by ineffective product lifecycle launches
4.Government regulation
5.Industry consolidation
Advanced Medical Isotope Corp. Presentation
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Nanobodies: Journey from Research to Commercial
Hilde Revets, Senior Research Fellow, Ablynx
Presentation at EIPG – VAPI-UPIP Symposium “Biotech and Advanced Therapies: Challenges and Opportunities” at the Faculty of Medicine and Pharmacy, Campus Jette, Vrije Universiteit van Brussel, Brussels 2013.
Biogen presentation1
The document outlines the 2007 business goals of Biogen Idec, including goals set by the CEO, CFO and management, and VP of R&D. The CEO's goal of having 100,000 patients on TYSABRI was not met. The CFO and management's goal of over 40% of revenue coming from international business was not met. The VP of R&D's goals of four new products launched or in new indications and six late-stage clinical programs were not met. The regulatory goal of six late-stage programs was achieved.
PBIO Investor Presentation
Pressure BioSciences is presenting their pressure cycling technology instruments and consumables. Their flagship product is the Barocycler 2320EXTREME instrument, which uses high pressure cycling to prepare biological samples for analysis. They have over 270 PCT systems installed worldwide and publications highlighting the advantages of PCT in biopharma sample preparation from discovery to clinical use. The company is poised for growth with their exclusive marketing agreement with SCIEX, expanded sales team, and focus on the multi-billion dollar biopharma market.
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
This document summarizes a presentation on FDA 483 trending topics and solutions. It discusses FDA definitions and common observations related to data integrity, documentation practices, visual inspection execution and documentation of defects, and container/closure integrity. For each topic, it provides examples of recent FDA inspection citations in biologics, devices, and drugs. It also discusses factors that may influence FDA inspections such as regulatory maturity, communication, investigator expertise, and company culture.
Cell Therapy Manufacturing: Regulations and Facilities
This document discusses the regulatory and manufacturing challenges of cell therapy products. It notes that cell therapies must be aseptically processed but cannot be fully sterilized like traditional drugs. The challenges include controlling differentiation of stem cells into the desired target cell type, developing potency assays, and dealing with variability in biological materials. Manufacturing challenges include developing aseptic processing methods, handling adventitious agents, and scaling up production capacity for either autologous or allogeneic use. Larger centralized facilities face quality oversight and logistical issues, while smaller regional facilities could better concentrate expertise, quality, and handling of incoming/outgoing cells and products.
Bharat biotech company Overview
Bharat Biotech’s research stems from the need to innovate and the necessity to address public health requirements of the developing nations, while adhering to IPR. Our business model is to support the advancement of technologies through strong collaborative research, and simultaneously support the establishment of strong innovative technology platforms for intellectual property reputed driven enterprise R&D.
APT_Indigo FactSheet FINAL
The document describes Aptuit INDiGO's accelerated drug development program. It offers integrated services to help clients advance molecules from candidate selection to clinical trials in as few as 52 weeks. This is significantly faster than the industry average of 122 weeks. Aptuit's program provides world-class expertise across preclinical and clinical development, API manufacturing, and regulatory submission preparation to streamline the process. It aims to reduce costs and development time while improving data quality for clients.
What's hot (15)
Ablynx Financial Presentation Half Year Results 2014
Ablynx Financial Presentation Half Year Results 2014
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
SQI Diagnostics BioFinance Presentation, Toronto, April 7, 2010
Finding a New Normal While Navigating Through Information Overload
Finding a New Normal While Navigating Through Information Overload
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
Cell Therapy Manufacturing: Regulations and Facilities
Cell Therapy Manufacturing: Regulations and Facilities
Similar to BA 401_Genenteach
New Venture Launch: Funding for trials for important new discovery
New Venture Launch: Funding for trials for important new discoveryWild Out West / Magnity Interactive
The company founder effectively life-hacked a $billion dollar OTC product and was awarded 6 patents for it. The funds raised were to prove efficacy and will probably be the only funding required before licensing.
We took a highly technical breifing and created a story that is both understandable and informative. We developed the brands, strategy, copy, graphics, and put together the deck and arranged key meetings with investors.
www.wildoutwest.comLaunch of a new Pharmaceutical Product
General Investor and partnership presentation for the launch of a new pharmaceutical product. Specifically funds the initial clinical trial and market tests.
Cgix
This investor presentation by Cancer Genetics, Inc provides an overview of the company and its proprietary genomic testing programs. CGI has locations in the US, India, and China serving biopharma, clinical, and research clients. It has launched 7 proprietary diagnostic products focused on hematologic and urogenital cancers, and is working to validate additional next generation sequencing panels. CGI's tests provide information to aid in diagnosis, prognosis, and therapeutic decision making for cancers like CLL, cervical cancer, and kidney cancer. The company is collaborating with academic centers to further develop and validate its genomic tests.
IGXT Jan 20 2017 Investor Presentation
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
Intelgenx Q4 Earnings Presentation
The document summarizes IntelGenx's Q4 and full year 2015 financial results. Key points include:
- Record revenue in Q4 2015 and full year 2015, demonstrating strong execution of their strategy.
- Continued growth of Forfivo XL sales, with Q4 2015 net sales increasing 24% over Q3 2015.
- Completion of construction of a new manufacturing facility that will lower costs and improve quality control.
- Strengthened management team to accelerate business development and product pipeline expansion.
- Outlook for continued revenue growth from commercialization efforts and new product opportunities utilizing their oral thin film technology platform.
wyeth Download Documentation Credit Suisse Group Healthcare Conference
This document is a presentation by Michael Kamarck from Wyeth discussing the company's manufacturing capabilities and strategies. It summarizes that Wyeth has a diversified business across pharmaceuticals, biotechnology, vaccines, and other areas. It has made over $3.5 billion in investments to support its biomanufacturing network and developed platform technologies to standardize processes. This allows production of multiple pipeline and commercial products using consistent materials and equipment. Wyeth has demonstrated the ability to increase yields and capacity for products like Enbrel and Prevnar through technological advances.
wyeth Credit Suisse Group Healthcare Conference
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
Igxt feb 1, 2017 investor presentation
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia/bipolar drugs. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and financial performance over recent years. It positions IntelGenx for continued growth by leveraging its drug delivery platform and oral thin film technology.
Pfizer at Deutsche Bank Securities Inc. Health Care Conference
Jeff Kindler, CEO of Pfizer, outlined the company's strategies for future growth at a healthcare conference. Pfizer plans to maximize revenues by optimizing its patent-protected portfolio, capitalizing on established products, and growing in emerging markets. It will establish a lower, more flexible cost base by aggressively managing costs and creating a more flexible operating model. Pfizer also aims to innovate its business model through changes to pharmaceutical operations and research and development. The overall goal is to drive greater total shareholder return.
Igxt nov 10 investor presentation
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's strategy to develop and commercialize improved drug delivery products using its oral thin film platform. Key points include successful commercial partnerships, a robust product pipeline including generic and branded products, positive clinical trial results, and a new manufacturing facility positioned for growth. Financial results show increasing revenue and adjusted EBITDA. The presentation positions IntelGenx as a leader in oral thin films with innovative technology and a clear strategy for growth.
Intelgenx aug 11
This document is an investor presentation for Innovative Drug Delivery Solutions that provides an overview of the company and its oral thin film drug delivery technology. It discusses the market opportunities for oral thin films in improving drug delivery. The presentation outlines IntelGenx's product pipeline focusing on their oral thin film formulations for migraines, erectile dysfunction, schizophrenia, and mild cognitive impairment. It also discusses the company's strengthened management team, new manufacturing facility, and financial performance positioning IntelGenx for growth in the oral thin film drug delivery market.
BioTime Investor Presentation 2016
The document discusses BioTime, Inc., a biotechnology company leading the regenerative medicine revolution. It summarizes BioTime's expertise in pluripotent stem cells and its focus on advancing two clinical programs - Renevia for facial aesthetics and OpRegen for dry age-related macular degeneration. It outlines upcoming milestones for these programs in 2016-2017, and how BioTime is unlocking value from its ownership stakes in public subsidiaries Asterias and OncoCyte, which are applying BioTime's stem cell technologies to therapies for conditions with high unmet medical need.
IntelGenX Investor Presentation March 30 2017
The presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia drugs. It also highlights a repurposed montelukast film for mild cognitive impairment currently in clinical trials. The presentation outlines IntelGenx's business strategy, partnership with Chemo, new manufacturing facility, and management team. It concludes that IntelGenx has a solid platform for growth due to its significant market potential and ability to build strategic partnerships.
ARSTAT_Introduction
ARSTAT Pharmaceuticals is seeking investors and partners as it prepares for an IPO. It has a pipeline of four first-in-class women's health products targeting large markets, including potential blockbusters Nuvocept and Premring. Nuvocept is a novel oral contraceptive designed for overweight/obese women, a major unmet need. Premring is a medicated vaginal ring to treat uterine fibroids and endometriosis. Both are in late-stage development and have the potential for high returns within 3-3.5 years due to ARSTAT's experienced team and advanced, low-risk programs. The company aims to complete development and sell assets at a valuation of at least $180M
Igxt aug 22 investor presentation
This presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's focus on using oral thin film technology to improve drug delivery and its product pipeline, which includes films for migraines, erectile dysfunction, schizophrenia, and mild cognitive impairment. The presentation also provides financial results, noting revenue growth and net income, as well as IntelGenx's new manufacturing facility and strengthened management team.
Access Pharmaceuticals (ACCP)
OneMedForum New York 2010 - Company Presentation. Access Pharmaceuticals, Inc., a emerging biopharmaceutical company that focuses on adding value to exciting product concepts in research by advancing those products through clinical development.
Advanced Medical Isotope Corp.- Investor Presentation
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing. It is working towards FDA approval for human cancer indications like skin cancer. RadioGel consists of radioactive yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. It is led by an experienced management team and advises by world-class medical and scientific boards.
Advanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
IntelGenx March 13, 2017 Investor Presentation
This presentation provides an overview of IntelGenx Corp., a drug delivery company focused on oral thin film technologies. Key points include:
- IntelGenx has a pipeline of product candidates using its VersaFilm drug delivery technology, including products for migraines, erectile dysfunction, schizophrenia, and repurposing drugs for brain diseases.
- The company has completed construction of a new manufacturing facility to produce oral thin films and lower costs.
- Management believes IntelGenx is well positioned for growth due to its drug delivery expertise, business model focusing on drug repurposing and first-to-file generics, and competitive manufacturing capabilities.
PIPEs Conference Presentations, November 2006
This document discusses a presentation made at the PIPEs Conference in November 2006. It summarizes the company's focus on regenerative medicine using human embryonic stem cells, including their programs in retinal pigment epithelium cells, hemangioblasts, and dermal cells. It outlines the company's progress in building out GMP facilities, preclinical studies, and plans to file an IND for their RPE program by late 2007. Key milestones for 2006 and 2007 are also summarized.
Similar to BA 401_Genenteach (20)
New Venture Launch: Funding for trials for important new discovery
New Venture Launch: Funding for trials for important new discovery
wyeth Download Documentation Credit Suisse Group Healthcare Conference
wyeth Download Documentation Credit Suisse Group Healthcare Conference
Pfizer at Deutsche Bank Securities Inc. Health Care Conference
Pfizer at Deutsche Bank Securities Inc. Health Care Conference
Advanced Medical Isotope Corp.- Investor Presentation
Advanced Medical Isotope Corp.- Investor Presentation
Advanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor Presentation
Recently uploaded
Cover Story - China's Investment Leader - Dr. Alyce SU
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
Discover the Beauty and Functionality of The Expert Remodeling Service
Unlock your kitchen's true potential with expert remodeling services from O'Brien Group Inc. Transform your space into a functional, modern, and luxurious haven with their experienced professionals. From layout reconfiguration to high-end upgrades, they deliver stunning results tailored to your style and needs. Visit obriengroupinc.com to elevate your kitchen's beauty and functionality today.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
9356872877Sattamatka.satta.matka.satta matka.kalyan weekly chart.kalyan chart.kalyan jodi chart.kalyan penal chart.kalyan today.kalyan open.fix satta.fix fix fix Satta matka nambar.❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...❼❷⓿❺❻❷❽❷❼❽ Dpboss Kalyan Satta Matka Guessing Matka Result Main Bazar chart
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night 2022 Vintage Roman Numerals Men Rings
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...Ksquare Energy Pvt. Ltd.
During the budget session of 2024-25, the finance minister, Nirmala Sitharaman, introduced the “solar Rooftop scheme,” also known as “PM Surya Ghar Muft Bijli Yojana.” It is a subsidy offered to those who wish to put up solar panels in their homes using domestic power systems. Additionally, adopting photovoltaic technology at home allows you to lower your monthly electricity expenses. Today in this blog we will talk all about what is the PM Surya Ghar Muft Bijli Yojana. How does it work? Who is eligible for this yojana and all the other things related to this scheme?Prescriptive analytics BA4206 Anna University PPT
Business analysis - Prescriptive analytics Introduction to Prescriptive analytics
Prescriptive Modeling
Non Linear Optimization
Demonstrating Business Performance Improvement
欧洲杯赌球-欧洲杯赌球买球官方官网-欧洲杯赌球比赛投注官网|【网址🎉ac55.net🎉】
【网址🎉ac55.net🎉】欧洲杯赌球是世界上历史最悠久的博彩公司之一。其历史可以追溯到十九世纪末，确切时间是1886年。这家英国公司拥有超过15000名员工，是博彩行业规模最大的公司。欧洲杯赌球是英国最受欢迎的实体博彩公司之一，其排名仅次于欧洲杯赌球，旗下2800家投注站遍布全英国。
IMG_20240615_091110.pdf dpboss guessing
Satta matka fixx jodi panna all market dpboss matka guessing fixx panna jodi kalyan and all market game liss cover now 420 matka office mumbai maharashtra india fixx jodi panna
Call me 9040963354
WhatsApp 9040963354
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka Indian satta Matka Dpboss Matka Kalyan Chart Matka Boss otg matka Guessing Satta The Most Inspiring Entrepreneurs to Follow in 2024.pdf
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
In this article, we will dive into the extraordinary life of Ellen Burstyn, where the curtains rise on a story that's far more attractive than any script.
2024-6-01-IMPACTSilver-Corp-Presentation.pdf
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Industrial Tech SW: Category Renewal and Creation
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Recently uploaded (20)
Cover Story - China's Investment Leader - Dr. Alyce SU
Cover Story - China's Investment Leader - Dr. Alyce SU
Discover the Beauty and Functionality of The Expert Remodeling Service
Discover the Beauty and Functionality of The Expert Remodeling Service
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Fin...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
PM Surya Ghar Muft Bijli Yojana: Online Application, Eligibility, Subsidies &...
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women Magazine
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
BA 401_Genenteach
- 1. Slide
- 5. Slide
- 6. Slide 2005 Most Admired Biotech Company
- 8. 1AVASTIN : drug for patients with previously untreated metastatic cancer of the colon or rectum Slide Overview Mission To be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. In 2003 Revenues : $3,300 million 79 % from product sales Net Income: $563 million In 2004 AVASTIN 1 was approved by FDA First nine months of 2004 sales of AVASTIN 15 % or $2,684,000 million TARCEVA & OMNITARG both drugs that Genentech promise to launch in the next year
- 9. Genentech Product Information (2001-2003) Slide ($ in millions)
- 13. Production Process Slide
- 14. Manufacturing Process Flow Chart (per Batch) Slide 2,000L 12,000L ( 0.75gm/L )
- 15. Slide Ultra Filtration Frozen Bulk Packaged Products
- 17. Slide
- 23. A model for all cancer indication Slide
- 24. Slide Capacity Planning Demand-upside Demand-Basecase Demand- Downside Sample Capacity Requirements Chart
- 25. Slide Plan Economic optimum a Total Product Demand (kilograms) Distribution of Possible Demand Scenerios
- 28. Plant Size and Design Slide
- 29. Conclusion Slide
- 30. Slide